AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01097408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo capsules
Study NCT00590395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18FDG (an FDA-approved radiopharmaceutical)
Description: Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
Study NCT00783198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641 6 Amb a 1-U
Description: SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
Study NCT00783198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641 12 Amb a 1-U
Description: SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
Study NCT00783198 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo sublingual tablets administered once daily
Study NCT03386838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03386838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Administered 100mg orally once daily for a maximum of 104 weeks
Study NCT03386838 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
Study NCT03386838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
Study NCT03386838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
Study NCT03386838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
Study NCT01801267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Description: Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
Study NCT01801267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular shunt
Description: Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
Study NCT00575484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline, then oral sodium chloride
Description: 2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
Study NCT00575484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline, then oral placebo capsule
Description: 20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
Study NCT00301613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF,1.0g/d
Study NCT00444561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramlintide acetate
Description: Clear, colorless, sterile solution for SC administration
Study NCT03268655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger extract
Description: 2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
Study NCT03268655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
Study NCT02692391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
Study NCT02692391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
Study NCT01433380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
Study NCT01433380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
Study NCT02654717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-07 Cream
Study NCT02654717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study NCT01316198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum
Description: 10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
Study NCT01316198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
Study NCT02541149 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample
Study NCT00539188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
Study NCT00539188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
Study NCT03288051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management
Description: Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
Study NCT03288051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
Study NCT03288051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
Study NCT04832269 — intervention group
Intervention type: OTHER
Intervention: Exposure to methylprednisolone during pregnancy
Description: Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
Study NCT03722277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variable load training
Description: Based on symptoms/strength measured in an isometric maximum strength test at five different angles of knee flexion- and extension, participants will be training with variable load during both concentric and excentric phase of the dynamic movement. Initially participants will start at 40% of symptom limited isometric strength, this will increase to 50% during the training period.
Study NCT03722277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional strength training
Description: Conventional strength training with rubber bands in knee flexion- and extension, additionally hip abduction- and adduction.
Study NCT06244290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate SNF
Description: toothpaste
Study NCT06244290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate SNF
Description: toothpaste
Study NCT06244290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Extra Whitening
Description: toothpaste
Study NCT06244290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sensodyne Extra Whitening
Description: toothpaste
Study NCT06244290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Fluoride (CDC)
Description: toothpaste
Study NCT06244290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Fluoride (CDC)
Description: toothpaste
Study NCT03868527 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection for biostatistical analysis about hematological diseases
Study NCT01685151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL (Dose 1)
Description: Ramelteon tablets for sublingual administration
Study NCT01685151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL (Dose 2)
Description: Ramelteon tablets for sublingual administration
Study NCT01685151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04139993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbiota-based Formulation RBX7455
Description: Given PO
Study NCT03297905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary and Integrative Therapies
Description: Intervention time period is 3 - 6 weeks.
Study NCT03297905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitative Care
Description: Intervention time period is 3 - 6 weeks.
Study NCT02401425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02401425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Study NCT02401425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study NCT02401425 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04363541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric pad for human external pain therapy
Description: An electric pad for local heat production will be put on the back of the patient for two hours
Study NCT00899392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emmi Pediatric Upper Endoscopy Patient Education Module
Description: Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
Study NCT02185924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Study NCT02185924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%
Study NCT00731926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligomerized litchi fruit extract
Description: 100mg at once twice a day for 1 month
Study NCT00731926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VItamin C + Vitamin E mixture
Description: Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
Study NCT02185924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%
Study NCT02185924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N/S 0.9%
Study NCT01536392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
Study NCT01536392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
Study NCT01536392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of 3 questionnaires at study visits taking about 5 minutes each time.
Study NCT01536392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Drug Diary
Description: Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
Study NCT04942977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: The system consists of the following elements:~1. Professional website at the hospital, which allows:~   * To set up an individualised care plan~  * To establish the patient's risk profile and targets for improvement.~  * Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred~  * Advise the patient on self-management strategies.~2. Mobile application software with the following functions:~   * Scheduled exercise sessions~  * Medication reminder~  * Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.)~  * Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~  * Training monitor: guides the patient in the performance of their exercise.~  * Access to certified health information for patients
Study NCT04942977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centre-based cardiac rehabilitation
Description: The physical activity consisted of a workout routine and aerobic cycling training. Patients are instructed to perform 150 minutes per week of moderate physical activity when the hospital phase finishes.
Study NCT01573234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MySkin patch
Description: Hydrogel and polyurethane film
Study NCT01573234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze and Patch
Description: Traditional Dressing
Study NCT03753789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
Study NCT02928263 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Other
Study NCT03339154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
Study NCT01269242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bindarit
Description: 300 mg bid, that is one 300 mg tablet twice a day for 6 months;
Study NCT01269242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bindarit
Description: 600 mg bid, that is two 300 mg tablets twice a day for 6 months
Study NCT01269242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: bindarit-matching placebo tablets for 6 months.
Study NCT02766140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1020 plus Docetaxel
Description: SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
Study NCT02766140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Docetaxel
Description: Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
Study NCT01526824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids (Lovaza)
Description: Lovaza, 1 gram orally daily
Study NCT04520438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukocyte and platelet rich fibrin
Description: L-PRF membrane and irrigation with L-PRF exudate in the same treatment session of NSPT
Study NCT04520438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical Periodontal treatment
Description: The control group only received NSPT (scaling and root planing) in one treatment session.
Study NCT04520438 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-Surgical Periodontal treatment
Description: The control group only received NSPT (scaling and root planing) in one treatment session.
Study NCT01578850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept 50mg once weekly + methotrexate with or without other DMARDs
Study NCT01578850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: etanercept placebo once weekly + methotrexate with or without other DMARDs
Study NCT01494623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain regions.
Study NCT01494623 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain regions.
Study NCT01630993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
Study NCT00263185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT00263185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study NCT00263185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Study NCT00263185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Study NCT00263185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Study NCT00263185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium carbonate
Study NCT00263185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT00263185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02923440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT02586779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whatsApp
Description: whatsApp application will be used for consultations.
Study NCT02586779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: without whatsApp
Description: whatsApp application will be not used for consultations.
Study NCT03485300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver and kidney function tests for patients with chronic liver or kidney diseases
Description: Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
Study NCT03485300 — intervention group
Intervention type: BEHAVIORAL
Intervention: Non compliance of the patient
Description: I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
Study NCT03485300 — intervention group
Intervention type: DRUG
Intervention: Drug or food interactions
Description: The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
Study NCT03419585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention systematic light exposure
Description: 30 minutes of intervention systematic light exposure daily
Study NCT03419585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison systematic light exposure
Description: 30 minutes of comparison systematic light exposure daily
Study NCT04032509 — intervention group
Intervention type: OTHER
Intervention: 2 x 5 mL blood sample
Description: 2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
Study NCT02547363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel
Study NCT02547363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study NCT00750152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT-500
Description: topical cream application up to 4 weeks
Study NCT00750152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo cream applied for up to 4 weeks
Study NCT02125591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CN-NINM PoNS
Description: Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
Study NCT02125591 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CN-NINM PoNS
Description: Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
Study NCT00096356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10 & Vitamin E